Hannonen 1998.

Study characteristics
Methods	Design: parallel Duration: 12 weeks Assessment: baseline and post‐intervention Country: Finland
Participants	Pain condition: fibromyalgia Population: women with fibromyalgia Minimum pain intensity: ≥ 4 on 0‐10 VAS Inclusion criteria Women aged 18‐65 Fulfilling ACR criteria for fibromyalgia ≥ 4 out of 0‐10 for pain, general health, sleep, and fatigue Exclusion criteria Severe physical health problems, major depression, psychosis, obsessive compulsive disorder Total participants randomised: 130 Age in years (mean): 48.7 Gender: 130/130 were female Pain duration in years (mean): 8.2
Interventions	Placebo n = 45 Inert Double‐dummy design Moclobemide 450‐600 mg n = 43 Reversible MAOI Flexible dose dependent upon efficacy Double‐dummy design Amitriptyline 25‐37.5 mg n = 42 TCA Flexible dose dependent upon efficacy Double‐dummy design
Outcomes	Pain intensity Sleep Mood Physical function AEs Withdrawal
Missing data methods	States ITT but no methods reported
Funding source	Partly supported by pharmaceutical: "The financial support by Roche Oy, Finland, is gratefully acknowledged."
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods NR
Allocation concealment (selection bias)	Low risk	The randomisation was organised centrally with sequentially numbered envelopes consisting of blocks of 6
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded, study drugs were identical, double‐dummy design
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes by blinded participants
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	States ITT but no methods reported Attrition Total: 38/130 (29.2%) Moclobemide 450‐600 mg: 13/43 (30.2%) Amitriptyline 25‐37.5 mg: 10/42 (23.8%) Placebo: 15/45 (33.3%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias identified